Selinexor 100 mg

DRUG2 trials

Sponsors

Karyopharm Therapeutics Inc, Hackensack Meridian Health

Conditions

Colorectal Cancer (CRC)Multiple MyelomaNon-Small Cell Lung Carcinoma (NSCLC)Other Solid Tumors

Phase 1

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

CompletedNCT04256707

Karyopharm Therapeutics IncColorectal Cancer (CRC), Non-Small Cell Lung Carcinoma (NSCLC), Other Solid Tumors

Start: 2020-01-14End: 2024-07-31Updated: 2025-03-19

Phase 2

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

SuspendedNCT04661137

Hackensack Meridian HealthMultiple Myeloma

Start: 2021-03-16End: 2027-02-01Target: 96Updated: 2026-02-10

Related Papers

Updated results from phase 2b study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma (MM) relapsing on current therapy.

Journal of Clinical Oncology2025-05-28

A Phase 2b Study of Selinexor in Combination with Pomalidomide in Patients with Pomalidomide-Refractory Multiple Myeloma

Blood2024-11-05

A Phase 2b Study of Selinexor in Combination with Carfilzomib, Daratumumab, or Pomalidomide in Patients with Multiple Myeloma Relapsing on Current Therapy

Blood2023-11-021 citations

A phase IIb study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy.

Journal of Clinical Oncology2023-06-01

Open-label phase 1/2 study evaluating the tolerability and antitumor activity of selinexor and pembrolizumab in colorectal cancer.

Journal of Clinical Oncology2022-01-191 citations

Open-label phase 1 study evaluating the tolerability and anti-tumor activity of selinexor and pembrolizumab in colorectal cancer.

Journal of Clinical Oncology2021-05-202 citations